A new nitrate derivative of piperazine: Its influence on platelet activity

Blood Coagulation and Fibrinolysis

Volumn 18, Issue 2, 2007, Pages 151-156

  Kostka, Barbara ^a   Sikora, Joanna ^a   Para, Jadwiga ^a   Krajewska, Urszula ^a   Korzycka, Lucyna ^a  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

Author keywords

Adhesion; Aggregation; In vitro model; Nitric oxide donors; Nitroglycerin; Nitrooxyanalogues of piperazine; Platelet shape change

Indexed keywords

1 (3 PIPERIDINEPROPIONYL) 4 (2 NITROXY 3 PIPERIDINEPROPYL)PIPERAZINE; ADENOSINE DIPHOSPHATE; COLLAGEN; GLYCERYL TRINITRATE; NITRIC ACID DERIVATIVE; ORGANIC NITRATE; PIPERAZINE; UNCLASSIFIED DRUG;

ARTICLE; CARDIOVASCULAR DISEASE; COMPUTER PROGRAM; CONTROLLED STUDY; EXPERIMENTAL MODEL; HUMAN; IN VITRO STUDY; KINETICS; PRIORITY JOURNAL; SCREENING; THROMBOCYTE ACTIVATION; THROMBOCYTE ADHESION; THROMBOCYTE AGGREGATION; THROMBOCYTE RELEASE REACTION; THROMBOCYTE SHAPE;

ADENOSINE DIPHOSPHATE; AUTOMATIC DATA PROCESSING; BLOOD PLATELETS; CELL SHAPE; COLLAGEN; DRUG EVALUATION, PRECLINICAL; HUMANS; KINETICS; NITRATES; NITRIC OXIDE DONORS; PIPERAZINES; PLATELET ACTIVATION; PLATELET ADHESIVENESS; PLATELET AGGREGATION;

EID: 33846931807     PISSN: 09575235     EISSN: None     Source Type: Journal    
DOI: 10.1097/MBC.0b013e3280147feb     Document Type: Article

References (26)

1. Kalinowski L, Matys T, Chabielska E, Buczko W, Malinski T. Angiotensin II AT1 receptor antagonists inhibit platelet adhesion and aggregation by nitric oxide release. Hypertension 2002; 40:521-527.
2. Kottke-Marchant K, Corcoran G. The laboratory diagnosis of platelet disorders. An algorithmic approach. Arch Pathol Lab Med 2002; 126:133-146.
3. Kamath S, Blann AD, Lip GYH. Platelet activation: assessment and quantification. Eur Heart J 2000; 22:1561-1571.
4. Rosas-Vargas H, Flores-Sequra A, Guizada-Claure B, Vargas-Alarcon G, Granados J, Salamanca F, et al. Endothelial nitric oxide synthase gene polymorphism in the Indian and Mestizo population of Mexico. Hum Biol 2003; 75:91-96.
5. Yamamoto T, Bing RJ. Nitric oxide donors. Proc Soc Exp Biol Med 2000; 225:200-206.
6. Napoli C, Ignarro LJ. Nitric oxide-releasing drugs. Ann Rev Pharmacol Toxicol 2003; 43:97-123.
7. Hagberg IA, Solvik UO, Opdahl H, Roald HE, Lyberg T. Inhalation of nitric oxide inhibits ADP-induced platelet aggregation and α-granule release. Platelets 1999; 10:382-390.
8. Gries A, Bode C, Peter K, Herr A, Bohrer H, Motsch J, et al. Inhaled nitric oxide inhibits human platelet aggregation, P-selectin expression, and fibrinogen binding in vitro and in vivo. Circulation 1998; 97:1481-1487.
9. Broadley AJ, Schmitt M, Frenneaux MP. Inhibition of platelet aggregation by nitric oxide donors improved with rest. Platelets 2003; 14:347-349.
10. Chudzik A, Wieclawska B, Watala C. Nitric oxide - its role and action in blood platelets and the influence and side-effects of the exogenous NO therapy on haemostasis [in Polish]. Acta Haematol Pol 1999; 30:107-115.
11. Jensen BO. Inhibition of platelet activation by nitric oxide. Platelets 1996; 7:345-346.
12. Korzycka L. The study on organic nitrates, part V. New derivatives of piperazine potential NO donors. J Pharm Pharmacol 2002; 54:445-450.
13. Ignarro LJ, Napoli C, Loscalzo J. Nitric oxide donors and cardiovascular agents modulating the bioactivity of nitric oxide: an overview. Circ Res 2002; 90:21-28.
14. Maurer-Spurej E, Pfeiler G, Maurer N, Lindner H, Glatter O, Devine DV. Room temperature activates human blood platelets. Lab Invest 2001; 8:581-592.
15. Walkowiak B, Michalak E, Koziolkiewicz W, Cierniewski CS. Rapid photometric method for estimation of platelet count in blood plasma in platelet suspension. Thromb Res 1989; 56:763-766.
16. Holme S, Moroff G, Murphy S. A multi-laboratory evaluation of in vitro platelet assays: the tests for extent of shape change and response to hypotonic shock. Transfusion 1998; 38:31-40.
17. Korzycka L, Bialasiewicz W, Szadowska A, Polakowski P, Graczyk J. Synthesis of asymetric 1,4-disubstituted piperazines and their psychotropic and cardiovascular actions. Part I. Pol J Pharmacol Pharm 1986; 38:535-553.
18. Sikora J, Krajewska U, Gietka M, Kostka B. The application of pig blood in the in vitro measurement of platelet adhesion. Pharmazie 2001; 56:187-188.
19. Bellavite P, Andrioli G, Guzzo P, Arigliano P, Chirumbolo S, Manzato F, et al. A colorimetric method for the measurement of platelet adhesion in microtiter plates. Anal Biochem 1994; 216:444-450.
20. Blockmans D, Deckmyn H, De Vos R, Vermylen J. Epinephrine induces a late thromboxane-dependent platelet shape change and enhances synergistically the shape change induced by other platelet agonists. Platelets 1996; 7:35-42.
21. Patscheke H, Worner P. Platelet activation detected by turbidometric shape-change analysis. Differential influence of cytochalasin B and prostaglandin E1. Thromb Res 1978; 12:485-496.
22. Kostka B, Pajak W. The aggregometer equipment for recording of transmittance (T) with the possibility of scale extension [in Polish]. Diagn Lab 1985; 21:43-47.
23. Keh D, Thieme A, Kurer I, Falke KJ, Gerlach H. Inactivation of platelet glycoprotein IIb/IIIa receptor by nitric oxide donor 3-morpholinosydnonimine. Blood Coagul Fibrinolysis 2003; 14:327-334.
24. Mondoro TH, Ryan BB, Hrinczenko BW, Schechter AN, Vostal JG, Alayash AI. Biological action of nitric oxide donor compounds on platelets from patients with sickle cell disease. Br J Haematol 2001; 112:1048-1054.
25. Korzycka L, Gorska D. Pharmacological investigation of nitrate derivatives of piperazine [abstract]. Pol J Pharmacol 2004; 56 (Suppl):140.
26. Korzycka L, Gorska D. The study of organic nitrates, Part VIII. Pharmacological activity and nitric oxide generation by nitrate derivatives of piperazine. Pol J Pharmacol 2005; 5:889-896.